Our 12 research and discovery units across China, Denmark, India, the
United Kingdom and the United States are designed to provide the best
scientific environment for the discovery and development of
Some of our global units are designed to work outside our core R&D organisation to drive concepts and projects that will expand and diversify our pipeline with disruptive medicines.
Across our global research and development network, we are working with both well established and cutting edge research technology platforms that provide us with the techniques, methods and processes that enhance our treatment accuracy and search.
Below you can get to know our global R&D centres even better.
We were the first global pharmaceutical company to establish a research facility in China. Located in Zhongguancun Life Science Park in Beijing, our research centre in China is a technology centre of excellence and plays a key role in our discovery of novel drug candidates.
In 2019, we launched an open innovation platform in China, INNOVO, to increase partnership with local academic institutions and small biotech companies.
Our centre in Bangalore operates as an integrated part of the project-centric development organisation. The team delivers data management, biostatistics and programming, medical writing, publishing, safety surveillance and medical communication for clinical trials and marketed products.
Måløv is our largest research centre, a site for innovation, idea generation, protein and peptide engineering and formulation, and preclinical testing of medicine candidates across our therapy areas.
The site houses our early drug discovery laboratories, as well as facilities for production upscaling and formulation of lead medicine candidates for clinical testing.
One of our teams at the research centre in Bagsværd is responsible for developing, formulating and manufacturing drug candidates for pre-clinical and clinical testing.
Another team is involved in the collection of adverse events, safety surveillance and event adjudication related to clinical trials, as well as the handling of complaints and product recalls, when needed.
Our centre in Søborg is a project-centric workplace focused on late-stage development across all our therapy areas.
This includes conducting and reporting on clinical trials, registering products, sharing the science, and engaging with health authorities, professional associations and the medical community.
Our research centre in Hillerød is our device innovation hub and a key location for our long-standing industry leadership in pioneering new medical devices and delivery technologies.
With its location in the heart of the University of Oxford medical campus, our research centre and transformational research unit in Oxford brings industry and academia closely together.
The research is focused on discovering novel disruptive therapies for cardiometabolic diseases by combining deep disease understanding of human biology with big data.
We have two stem cell research and clinical manufacturing facilities located in the San Francisco Bay area: University of California, San Francisco (UCSF) in San Francisco’s Mission District, and the other in Fremont.
These teams leverage stem cell technology to find new treatments for patients with diabetes and heart failure, and are exploring other high need areas such as neurology and ophthalmology.
Novo Nordisk Research Center Indianapolis, Inc. (NNRCII) was established in late 2015 when we acquired Calibrium and MB2, two private companies co-founded by Dr. Richard DiMarchi that were focused on developing peptide-based drug candidates for treatment of diabetes and obesity. Today, NNRCII is the home of an elite research team working in unison within our global research mission to transform the management of cardio-metabolic diseases.
Our scientists are focused on innovative discovery projects pertaining to diabetes, obesity and related diseases. We develop and employ cutting-edge biotechnologies to identify, refine, and select suitable drug candidates that possess novel mechanisms of biological action through collaboration with internationally acclaimed academic centres of excellence.
The Novo Nordisk Boston Innovation Hub is the headquarters for Global R&D Business Development across all of our therapeutic and technology areas. Containing functions in Business Development, Search & Evaluation, and Alliance Management, the Boston Innovation Hub houses the full complement of business functions needed for our external partnering activities. Having a physical presence in the one of the world’s largest life sciences ecosystem is part of our strategy to access the high level of innovation that the US has to offer.
In Boston, we work with local companies, venture capitalists, universities, and teaching hospitals to access technologies and therapeutic molecules that allow us to help patients in all of our current therapeutic areas. Through a variety of partnership models, we use this innovation to help advance and expand its product portfolio.
Our research centre in Seattle is focused on early discovery projects within diabetes, obesity and chronic kidney disease. The unit's scientists apply advanced technologies to identify protein-based therapies for obesity and the prevention and treatment of type 1 diabetes. Furthermore, a dedicated team of device engineers are working with digitalisation and connectivity of medical devices for improved treatment outcome.